Vaccine News and Research

Latest Vaccine News and Research

As covid vaccinations slow, parts of the US remain far behind 70% goal

July Fourth was not the celebration President Joe Biden had hoped for, as far as protecting more Americans with a coronavirus vaccine.

7 Jul 2021

Study addresses potential interrelations between AID/APOBECs and the SARS-CoV-2 virus

Together with their multifaceted action mechanisms, activation-induced cytidine deaminase (AID) and so-called APOBEC proteins are important factors in the body's immune response and offer fast and effective protection against a large number of DNA and RNA viruses.

7 Jul 2021

Real-world evidence for effectiveness of vaccination against 4 SARS-CoV-2 VOCs in Canada

Toronto-based researchers recently conducted a study to determine the effectiveness of BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and ChAdOx1 (AstraZeneca) vaccines against symptomatic COVID-19 infection caused by the Alpha, Beta, Gamma, and Delta variants between December 2020 to May 2021.

7 Jul 2021

Interleukin-6 antagonists benefit hospitalized patients with COVID-19

Findings from a study published today [6 July] in the Journal of the American Medical Association (JAMA) have prompted new World Health Organization (WHO) recommendations to use interleukin-6 antagonists in patients with severe or critical COVID-19 along with corticosteroids.

7 Jul 2021

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.

7 Jul 2021

COVID-19 vaccination may be stemming evolution of “fitter” SARS-CoV-2 variants

Researchers in the United States and India have presented the first known evidence that the rollout of coronavirus disease 2019 (COVID-19) vaccination is restricting the evolutionary and immune escape pathways accessible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection.

6 Jul 2021

Eight new research projects to explore COVID-19 variants of concern in Canada

Eight new research projects are getting underway in Canada to investigate COVID-19 variants of concern (VOCs) and variants of interest (VOIs).

6 Jul 2021

Laboratory manufactured protein spikes mimic key features of SARS-CoV-2 virus

A new international study has found that the key properties of the spikes of SARS-CoV-2 virus which causes COVID-19 are consistent with those of several laboratory-developed protein spikes, designed to mimic the infectious virus.

6 Jul 2021

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

New research released on the medRxiv* preprint server has measured antibody responses in 71 mRNA vaccinated adults (54 vaccinated with Pfizer and 17 vaccinated with Moderna).

6 Jul 2021

Preliminary study shows no need to cease breastfeeding following COVID-19 vaccination

A new study of 13 breastfeeding mothers has shown that components from the COVID-19 vaccine were not found in any breastmilk.

6 Jul 2021

Developing a face mask that can detect COVID-19

A face mask has been developed that can detect COVID-19. News-Medical spoke to the researchers behind this idea to find out more about how it works.

6 Jul 2021

COVID-19 recovered vaccinated individuals more protected from Delta variant

The B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in October 2020, has led to new outbreaks of the infection and new waves of the pandemic. This infectious lineage has resulted in the generation of sub-lineages such as B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.617.3.

6 Jul 2021

Two chemoattenuated PfSPZ malaria vaccines provide strong and lasting protection

A team of researchers recently optimized regimens for CVac, wherein aseptic, purified, cryopreserved, and infectious PfSPZ were inoculated and mixed with PYR and CQ.

5 Jul 2021

Study says mRNA COVID vaccines are effective against Lambda variant

Researchers in the United States have conducted a study suggesting that the coronavirus disease 2019 (COVID-19) vaccines that are currently being rolled out in many countries should be effective against the C.37 lineage (lambda variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

A study conducted by researchers from Maryland in the United States has found no correlation between the symptoms that develop following vaccination against coronavirus disease 2019 (COVID-19) and the antibody responses that are generated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Scientists identify breakthrough cases of SARS-CoV-2’s delta variant in fully vaccinated individuals

In a recent study conducted at the Baylor College of Medicine, Houston, USA, scientists have identified six vaccine breakthrough cases caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

The findings reveal that the two-dose regimen of the vaccine is almost 90% effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, the vaccine shows high efficacy against the B.1.1.7 variant (Alpha) of SARS-CoV-2.

5 Jul 2021

Rapid quantification of SARS-CoV-2 Spike-specific T cells by direct peptide stimulation of whole peripheral blood

To understand both the correlates of protection induced by vaccinations and the necessary immune responses to manage the COVID-19, researchers from Singapore used an alternative method to closely evaluate the kinetics and magnitude of specific T cell responses to SARS-CoV-2 infection. Their work was posted to the bioRxiv* preprint server while awaiting peer review.

5 Jul 2021

Phylogenetic network analysis reveals recombinant origin of the SARS-CoV-2 alpha (B.1.1.7) variant

Researchers from the U.S. recently used the phylogenetic network approach to analyze the origin of the VOC202012/01 (alpha) or the PANGO Lineage B.1.1.7 variant, which was first reported in U.K. in 2020 and soon spread to other countries. This study is published on the bioRxiv preprint server while the paper undergoes peer review.

5 Jul 2021

Vaccine News and Research

Latest Vaccine News and Research

As covid vaccinations slow, parts of the US remain far behind 70% goal

Study addresses potential interrelations between AID/APOBECs and the SARS-CoV-2 virus

Real-world evidence for effectiveness of vaccination against 4 SARS-CoV-2 VOCs in Canada

Interleukin-6 antagonists benefit hospitalized patients with COVID-19

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

COVID-19 vaccination may be stemming evolution of “fitter” SARS-CoV-2 variants

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Eight new research projects to explore COVID-19 variants of concern in Canada

Laboratory manufactured protein spikes mimic key features of SARS-CoV-2 virus

Study examines evolution and avidity of anti-SARS-CoV-2 IgG antibodies after mRNA vaccination

Preliminary study shows no need to cease breastfeeding following COVID-19 vaccination

Developing a face mask that can detect COVID-19

COVID-19 recovered vaccinated individuals more protected from Delta variant

Two chemoattenuated PfSPZ malaria vaccines provide strong and lasting protection

Study says mRNA COVID vaccines are effective against Lambda variant

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

Scientists identify breakthrough cases of SARS-CoV-2’s delta variant in fully vaccinated individuals

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

Rapid quantification of SARS-CoV-2 Spike-specific T cells by direct peptide stimulation of whole peripheral blood

Phylogenetic network analysis reveals recombinant origin of the SARS-CoV-2 alpha (B.1.1.7) variant

eBook: Advancing infectious disease vaccine development eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Vaccine News and Research

Latest Vaccine News and Research

eBook: Advancing infectious disease vaccine development eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in